On May 26, Smoore International fell 3.01% in regular trading, trading at HK$9.76 per share, with trading volume of HK$16.20 million.

On the news front, the U.S. FDA previously approved for the first time a non-tobacco flavored e-cigarette product through its PMTA review process, which had propelled Smoore International shares up over 20% within the month. Since May 14, the stock has entered a sustained pullback phase. After a brief stabilization and rebound on May 22, the stock weakened again, with current price action continuing to reflect profit-taking pressure. Trading volume has contracted significantly, indicating pronounced wait-and-see sentiment among market participants.

Institutions remain constructive on the medium-to-long term thesis for Smoore International, noting that its underage-user identification technology was a key consideration in the FDA approval process. Core client products and the company's proprietary brands are expected to accelerate through the regulatory pipeline, positioning Smoore as a direct beneficiary of the compliant market recovery.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)